4.6 Article

Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013

期刊

MATURITAS
卷 75, 期 4, 页码 392-396

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.maturitas.2013.05.013

关键词

Osteoporosis; Fracture; FRAX; Guideline

资金

  1. Servier
  2. Consilient Health
  3. Amgen/GSK
  4. Shire
  5. Eli Lilly
  6. Amgen
  7. GSK
  8. MSD
  9. Novartis
  10. Proctor Gamble
  11. ProStrakan
  12. Roche
  13. Medtronic
  14. Tethys
  15. GE Lunar
  16. Bayer
  17. Hologic
  18. Lilly
  19. Merck
  20. Pfizer
  21. Warner-Chilcott
  22. Innovus 3i
  23. Alliance for Better Bone Health
  24. Biointetica
  25. Celtrix
  26. D3A
  27. General Electric
  28. Kissel
  29. Medimaps
  30. Merck Research Labs
  31. Sanofi-Aventis
  32. UBS
  33. Olympus
  34. Synthes
  35. Stryker
  36. Biomet
  37. Medical Research Council [MR/K006312/1] Funding Source: researchfish
  38. MRC [MR/K006312/1] Funding Source: UKRI

向作者/读者索取更多资源

Since the launch in 2008 by the National Osteoporosis Guideline Group (NOGG), of guidance for the diagnosis and management of osteoporosis in postmenopausal women and older men in the UK there have been significant advances in risk assessment and treatment. These have been incorporated into an updated version of the guideline, with an additional focus on the management of glucocorticoid-induced osteoporosis, the role of calcium and vitamin D therapy and the benefits and risks of long-term bisphosphonate therapy. The updated guideline is summarised below. The recommendations in the guideline are intended to aid management decisions but do not replace the need for clinical judgement in the care of individuals in clinical practice. (C) 2013 Elsevier Ireland Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据